Edition:
United Kingdom

CTI Biopharma Corp (CTIC.OQ)

CTIC.OQ on NASDAQ Stock Exchange Capital Market

5.10USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$5.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
86,618
52-wk High
$5.19
52-wk Low
$2.46

Latest Key Developments (Source: Significant Developments)

CTI BioPharma to receive $10 mln milestone payment for Trisenox
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Cti Biopharma Corp ::CTI BIOPHARMA TO RECEIVE $10 MILLION MILESTONE PAYMENT FOR TRISENOX®.CTI BIOPHARMA - ‍TO RECEIVE $10 MILLION MILESTONE PAYMENT FROM TEVA PHARMACEUTICAL INDUSTRIES RELATED TO U.S. FDA APPROVAL OF TRISENOX​.  Full Article

CTI Biopharma Corp Says Co Entered Into A Loan And Security Agreement​
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA CORP - ‍ON NOVEMBER 28, 2017, CTI BIOPHARMA CORP ENTERED INTO A LOAN AND SECURITY AGREEMENT​.CTI BIOPHARMA CORP - ‍PURSUANT TO AGREEMENT, LENDER HAS AGREED TO MAKE A SENIOR SECURED TERM LOAN OF UP TO $18 MILLION​.CTI BIOPHARMA CORP - ‍FIRST $16 MILLION OF TERM LOAN WAS FUNDED ON NOVEMBER 28, 2017​.  Full Article

CTI BIOPHARMA FILES FOR MIXED SHELF OF UP TO $200 MLN‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Cti Biopharma Corp ::CTI BIOPHARMA CORP FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING‍​.  Full Article

CTI Biopharma reports third quarter 2017 financial results
Monday, 6 Nov 2017 

Nov 6 (Reuters) - CTI Biopharma Corp ::CTI Biopharma reports third quarter 2017 financial results.Q3 loss per share $0.28.CTI Biopharma Corp - ‍total revenues for q3 were $1.7 million compared to $4.4 million.  Full Article

CTI BioPharma announces retirement of president and CEO
Monday, 3 Oct 2016 

CTI BioPharma Corp : James Bianco,CTI BioPharma's president and chief executive officer, has retired from company . CTI BioPharma announces retirement of president and CEO .Richard Love, a director of CTI BioPharma since 2007, has been appointed to serve as interim president and CEO.  Full Article

CTi biopharma granted 180 day extension by NASDAQ to regain compliance
Thursday, 22 Sep 2016 

CTi Biopharma Corp : CTi Biopharma granted 180 day extension by NASDAQ to regain compliance with minimum bid price rule .On September 20, 2016, NASDAQ listing qualifications granted co until March 20, 2017, regain compliance with minimum bid price rule.  Full Article

CTI Biopharma Q2 loss per share $0.07
Thursday, 4 Aug 2016 

CTI Biopharma Corp : Q2 loss per share $0.07 . CTI Biopharma reports second quarter 2016 financial results .Total revenues for q2 ended june 30, 2016, were $7.4 million versus $1.1 million.  Full Article

BRIEF-Cti Biopharma Reports Q1 EPS Loss Per Share Of $0.08

* AS OF MARCH 31, 2018, CASH AND CASH EQUIVALENTS TOTALED $104.6 MILLION, COMPARED TO $43.2 MILLION AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage: